ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Eli Lilly and Co

Eli Lilly and Co (LLY)

926,565
15,88
( 1,74% )
Aktualisiert: 17:44:11

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
926,565
Gebot
-
Fragen
-
Volumen
926.091
911,1845 Tagesbereich 926,565
547,61 52-Wochen-Bereich 972,53
Marktkapitalisierung
Handelsende
910,69
Handelsbeginn
914,35
Letzte Trade
1
@
926.565
Letzter Handelszeitpunkt
17:44:11
Finanzvolumen
US$ 850.508.407
VWAP
918,3854
Durchschnittliches Volumen (3 Mio.)
3.053.245
Ausgegebene Aktien
950.425.778
Dividendenrendite
0.56%
Kurs-Gewinn-Verhältnis
167,11
Gewinn pro Aktie (EPS)
5,51
Erlöse
34,12B
Nettogewinn
5,24B

Über Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, a... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Indianapolis, Indiana, USA
Gegründet
-
Eli Lilly and Co is listed in the Pharmaceutical Preparations sector of the New York Börse with ticker LLY. The last closing price for Eli Lilly was US$910,69. Over the last year, Eli Lilly shares have traded in a share price range of US$ 547,61 to US$ 972,53.

Eli Lilly currently has 950.425.778 shares in issue. The market capitalisation of Eli Lilly is US$865,54 billion. Eli Lilly has a price to earnings ratio (PE ratio) of 167.11.

Option-Flow Eli Lilly (LLY)

Gesamtfluss

Bullisch

Nettoprämie

28M

Calls / Puts

144,29%

Käuf. / Verkä.

89,14%

OTM / ITM

48,05%

Sweeps

0,58%

LLY Neueste Nachrichten

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

October 2, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as...

Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials

Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials PR Newswire INDIANAPOLIS, Oct. 2, 2024 Indiana...

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis

New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis PR...

Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease

Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire INDIANAPOLIS, Sept. 24, 2024 Japan is the second major market where...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
143.024.86902195134883.545927.4397876.892023212905.14479325CS
4-12.575-1.33899099176939.14939.86863.652627863907.06710629CS
1253.6556.1466817885872.91972.53747.553053245886.28900025CS
26166.78521.9517491906759.78972.53718.32904413856.54263424CS
52329.51555.1905200569597.05972.53547.613034845754.12637908CS
156689.295290.510810469237.27972.53231.872975846486.24955775CS
260818.815759.921113689107.75972.53101.363255430341.53794334CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
TCSContainer Store Group Inc
US$ 13,25
(30,29%)
53,16k
WOLFWolfspeed Inc
US$ 11,1746
(17,63%)
7,33M
AMPXAmprius Technologies Inc
US$ 1,335
(16,09%)
809,56k
NUVBPanacea Acquisition Corp
US$ 2,30
(14,43%)
1,2M
CURVTorrid Holdings Inc
US$ 3,79
(12,80%)
416,24k
SRFMSurf Air Mobility Inc
US$ 2,445
(-25,23%)
1,46M
EBFEnnis Inc
US$ 20,65
(-14,35%)
120,6k
TISITeam Inc
US$ 21,90
(-12,92%)
33,34k
PNSTPinstripes Holdings Inc
US$ 0,5803
(-7,86%)
55,53k
EXTOAlmacenes Exito SA
US$ 4,46
(-5,71%)
26,53k
PLTRPalantir Technologies Inc
US$ 43,47
(-0,11%)
29,43M
UBERUber Technologies Inc
US$ 85,365
(9,55%)
27,35M
BACBank of America Corporation
US$ 42,03
(5,15%)
24,68M
NIONIO Inc
US$ 6,251
(0,50%)
20,55M
ALTMArcadium Lithium plc
US$ 5,545
(0,27%)
17,43M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock